We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over the past week, the FDA issued a proposed rule on laboratory developed tests, final guidance on labeling for dosing of human prescription drugs and biological products and draft guidance on stimulant drug use disorders.